Osgood Schlatter’s Disease & Osteoarthritis

April 25,2018

Macquarie Stem Cells has provided this information to educate the public based on peer reviewed, published scientific and medical documents. We don’t aim to encourage consumers to seek out such treatments prior to an assessment by a health professional to determine your suitability for treatment. This is obtained directly from NCBI Pubmed Literature.  This study was funded by Arthrex. We aim to provide you with an unbiased range of treatments that are available aside from biological therapy, this is discussed in ‘supporting information>other-options’  page on our website

Published: Joints Journal – 2017

Successful Treatment of Osgood Schlatter Disease (OSD)

Published: September, 2017

PART 1 – OSD treatment based on the publication

PART 2 – OSD leading to osteoarthritis treated with based on the publication + biological intervention

PART 1 –


Osgood-Schlatter disease is a common cause of knee pain in growing adolescents. It is an inflammation of the area just below the knee where the tendon from the kneecap (patellar tendon) attaches to the shinbone (tibia).

Osgood-Schlatter disease most often occurs during growth spurts, when bones, muscles, tendons, and other structures are changing rapidly. Physical activity is known to place additional stress on bones and muscles, children who participate in athletics  (especially running and jumping sports) are at an increased risk for this condition. However, less active adolescents may also experience this problem.(Orthoinfo, 2018)

“Treatment with analgesics, physiotherapy, and reduction of physical activity is recommended. However, the duration of symptoms can be lengthy. Injections of autologous-conditioned plasma (ACP) are increasingly being used for a variety of musculoskeletal conditions.  The growth factors contained in ACP are thought to influence mechanisms essential for tissue repair (e.g., modulation of inflammatory processes, chemotaxis, cell proliferation and migration, and matrix synthesis and differentiation).  Therapeutic application of these treatments is safe and minimally invasive, and the preparation of conditioned plasma from autologous blood is simple. Here, we describe a case of OSD presenting in a young adult male after resolved childhood OSD and a case of treatment-resistant OSD in an adolescent male.” (Danneberg D., 2017)

Case 1

“A 23-year-old male tennis player with a childhood history of OSD resolving with age presented with right knee pain after a direct frontal impact onto the head of the tibia. On examination, he had tenderness at the tibial tuberosity and a small effusion, but no overlying erythema or limited range of motion. Knee X-rays demonstrated patellar tendon edema, and a sliver-like osseous density anterior to the apophysis of the tibial tuberosity, confirming the diagnosis of OSD. Sonographic imaging revealed a fluid layer or inflammatory fluid collection around the completely healed apophysis. Gait analysis revealed internal rotation of the lower leg.” (Danneberg D., 2017)

Case 2

“A 14-year-old male patient presented with reoccurring bilateral knee pain from persisting treatment-resistant OSD. He first presented with knee pain at the age of 12, and played tennis 5 to 6 times/week. Previous repeated therapeutic interventions included extended resting phases, orthopedic insoles, physiotherapy, ultrasound therapy, and pulsed magnetic field therapy. Due to the existing diagnosis of treatment-resistant OSD, only confirmatory sonography and magnetic resonance imaging (MRI) scans were performed.” (Danneberg D., 2017)



“Patients received once-weekly subcutaneous injections of 1 mL ACP on either side of the palpable Osgood–Schlatter lesion/swelling, for a total of three to five applications. The first patient, was treated in the right knee for 3 weeks, and the second patient in both knees for 4 weeks.” (Danneberg D., 2017)


“There were no postinjection complications. The first patient experienced a subjective pain reduction of approximately 50% after one injection. After 3 weeks, the patient was pain-free and able to return to sport. The second patient was pain-free after 6 weeks and able to return to sports; he has not experienced a relapse in OSD since treatment.” (Danneberg D., 2017)


PART 2 –
Further Degenerative Case Leading to Osteoarthritis

Biological Treatment Case

A 47-year-old male,  presented with complaints of arthritic pain in both of his knees. A formerly athletic patient, riding up to 300 km and alternatively running up to 50 km per week. The patient’s active lifestyle through his 30’s through to early 40’s has stressed his joints greater than the average male. Patient’s early OSD in combination with persistent training and competing lead him to develop early stages of osteoarthritis in his knees at a young age. Current knee X-ray reports indicate mild loss of articular cartilage and residual damage to the tibial tuberosity. This is consistent with many OSD and osteoarthritis cases.

Image: Above mentioned patient competing in riding events, France.

Initial treatment followed similar treatment protocols as mentioned previously in the publication. The patients own biological products were harvested and re-injected to repair arthritic degeneration and to regulate constant pain. The fat was harvested using liposuction from the abdomen. The biological treatment was administered into both knees under ultrasound guidance. No complications were observed.

We are unable to inform you about the patient results on this page, however we can do so at a consultation.

For this patient, the ongoing progress will be monitored after 1, 3, 6 and 12 months respectively.


REF 1: Orthoinfo.aaos.org. (2018). Osgood-Schlatter Disease (Knee Pain) – OrthoInfo – AAOS. [online] Available at: https://orthoinfo.aaos.org/en/diseases–conditions/osgood-schlatter-disease-knee-pain/ [Accessed 13 Feb. 2018].

REF 2: Danneberg, D. (2017). Successful Treatment of Osgood–Schlatter Disease with Autologous-Conditioned Plasma in Two Patients. Joints, 05(03), pp.191-194.

Keywords: Osgood–Schlatter disease, osteoarthritis, macquarie stem cells, Dr. Ralph Bright, treament of arthritis, biological treatment, biological intervention


Remember, any surgical or invasive procedure carries risks. Before proceeding, you should seek a second opinion from an appropriately qualified health practitioner.

Speak with one of our consultants today